Study summary
One felzartamab course did not help people whose disease resisted rituximab
What was tested
A 5-month course of felzartamab in adults with membranous nephropathy and nephrotic syndrome that had not responded to rituximab.
What they found
- Proteinuria at 12 months was similar to baseline.
- Anti-PLA2R antibodies fell only temporarily.
- Treatment was safe and well tolerated.
What it means
Suggests rituximab-resistant disease may need different or combined approaches.
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.